Clinical Trial Update: Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation [Phase 3]

View source ↗

Summary

Phase 3 trial of flecainide acetate inhalation solution for cardioversion in recent-onset symptomatic atrial fibrillation was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Atrial Fibrillation

Drugs mentioned

• flecainide acetate inhalation solution (flecainide acetate)

Snippet

Sponsor: InCarda Therapeutics, Inc. | Conditions: Paroxysmal Atrial Fibrillation | Phase 3 | Status: TERMINATED